Publicaciones en las que colabora con Pedro Berraondo López (15)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

  2. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

2013

  1. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein

    Cancer Research, Vol. 73, Núm. 1, pp. 139-149

  2. Eradication of liver-implanted tumors by semliki forest virus expressing IL-12 requires efficient long-term immune responses

    Journal of Immunology, Vol. 190, Núm. 6, pp. 2994-3004

  3. Interleukin-15 in gene therapy of cancer

    Current Gene Therapy, Vol. 13, Núm. 1, pp. 15-30

2012

  1. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

2011

  1. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010

    Cancer Immunology, Immunotherapy

  2. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

  3. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

    Gut, Vol. 60, Núm. 3, pp. 341-349

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

2007

  1. Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells

    Inmunologia, Vol. 26, Núm. 3, pp. 121-126

2001

  1. Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12

    Journal of Virology, Vol. 75, Núm. 19, pp. 9068-9076